Tag: Business of health care

  • Lankenau Medical Center’s new president is Anna Michelle Brandt

    Lankenau Medical Center’s new president is Anna Michelle Brandt

    Main Line Health appointed Anna Michelle Brandt president of its Lankenau Medical Center in Wynnewood, the nonprofit health system announced Monday.

    Brandt mostly recently worked as chief operating officer at University Hospital, a 519-bed academic medical center in Newark, N.J., which Main Line’s new CEO Ed Jimenez led before taking over at Main Line.

    The new Lankenau president also worked previously with Jimenez at UF Health Shands Hospital in Florida.

    Brandt succeeds Katie Galbraith, who left Lankenau in September after about three years to lead New England Baptist Hospital in Boston.

    Lankenau, a level 2 trauma center, sits in Lower Merion Township at the intersection of West Philadelphia and Montgomery and Delaware Counties.

    It also has the Lankenau Institute for Medical Research, which has programs in cancer, cardiovascular, autoimmune, and other diseases.

  • New Philadelphia-area cardiovascular surgery centers are pulling profitable procedures from hospitals and charging less

    New Philadelphia-area cardiovascular surgery centers are pulling profitable procedures from hospitals and charging less

    At AMS Surgery Center in suburban Montgomery County, patients can park right in front of the entrance, walk through just a few doors, and undergo cardiac procedures in a sterile operating room with equipment as high-tech as in any hospital procedure room.

    In the year and a half since its first patient underwent a cardiac catheterization, the center has performed more than 1,000 cardiac procedures that previously required patients to go to full-service hospitals.

    The Horsham center showcases a new front as sophisticated healthcare procedures move to freestanding outpatient medical facilities, promising to save patients money. The shift also adds to the financial pressures facing the region’s hospital-centered health systems.

    Four centers have opened or are in the final stages of approvals in Southeastern Pennsylvania. Their arrival comes after state lawmakers in 2022 broadly expanded the types of procedures allowed outside hospitals to include cardiac catheterizations, pacemaker implants, and other treatments that until then had to be done in a hospital.

    Pennsylvania is the first Northeastern state to allow the minimally invasive procedures in freestanding surgery centers, but Southern states like Florida, Louisiana, and Texas have permitted the practice for decades, experts said. Research has found surgery centers generally are as safe as outpatient departments in hospitals.

    An independent physicians group, Bryn Mawr Medical Specialists Association, opened Heart & Vascular Center of the Main Line — the Philadelphia region’s first such center — in late 2022. in Bryn Mawr. AMS Surgery Center in Horsham performed its first procedure in the fall of 2024, initially treating only Medicare patients. It added patients with private insurance last summer.

    The market has continued to rapidly expand: ReVaMP Heart & Vascular Surgery Center in Center City started treating Medicare patients last fall. The Ambulatory Cardiovascular Center of Pennsylvania, near King of Prussia, expects to perform its first procedures on patients next month.

    Medicare pays the centers about a third less than hospital outpatient departments for the same procedures, but the centers have significantly lower costs, allowing them to be profitable. Medicare pays physicians the same wherever procedures are done.

    Independent cardiology groups traditionally have performed interventional procedures, such as implanting stents and pacemakers, in hospitals. Some are jumping at the opportunity to expand through the surgery centers, where they can have a financial stake in the entire operation.

    “We’ve always been very fiercely independent, fiercely entrepreneurial, and patient-centered,” said Richard Borge, an AMS interventional cardiologist who is medical director for the group’s surgery center.

    How much cardiac care — among the most profitable business lines for hospitals — will move out of hospital outpatient departments remains unknown. But cardiac surgical clinics will not take over heart care to the extent seen when outpatient orthopedic centers began offering hip and joint replacements, predicted Lauren Clementi, a senior vice president at Kaufman Hall, a Chicago consulting firm.

    “This one’s a little trickier because the acuity of patients,” she said.

    Cardiologists will continue treating many patients with complex medical needs in hospitals, which remain the only option for riskier procedures such as open-heart surgeries.

    Gregory Schmitt went to AMS Surgery Center to undergo procedures for a heart stent and stents in both legs. The retired machine-shop owner, who lives in Ivyland, called such centers great for patients.

    “I highly recommend it. It’s much easier than trying to navigate a hospital,” Schmitt said.

    How we got here

    Healthcare has been shifting away from requiring overnight hospital stays, even for common procedures like cataract surgery. The trend started decades ago with same-day procedures in hospitals, followed by the rise of freestanding surgery centers.

    In cardiology, people now commonly receive stents and pacemakers as outpatient care. But until recently, doctors had to implant the devices in a hospital.

    “Once upon a time, every patient we cathed had to spend the night in the hospital,” said veteran cardiologist Mark Victor, referring to cardiac catheterization.

    With the rise of outpatient procedures, Victor said, the question for many clinicians became: “If they’re hospital ambulatory, why do they have to be in the hospital at all?”

    Victor has long advocated for the adoption of outpatient cardiology procedures as the CEO of Cardiology Consultants of Philadelphia. The large cardiology practice joined last year a national private-equity backed group, Cardiovascular Logistics, and will soon start performing surgical procedures at the center opening near King of Prussia.

    In 2020, Medicare started paying for outpatient cardiac catheterizations — which entail running a catheter through a blood vessel in the thigh or wrist to examine the heart and install devices like stents.

    Richard Borge is medical director of AMS Cardiology Surgery Center in Horsham, whose arrival is moving advanced cardiac care from hospitals to outpatient clinics.

    Even then, Pennsylvania rules required cardiac catheterizations to occur in an acute-care hospital, according to Stephen Abresch, director of government affairs for the Ambulatory Surgery Center Association, a national trade group in Alexandria, Va.

    Pennsylvania lawmakers cleared the way for expansion by eliminating that restriction in 2022 as part of a broad expansion of what the state’s surgery centers were allowed to do. “It had been a quarter century since the state had gone in and reviewed that,” he said.

    Beginning this year, Medicare started paying surgery centers to perform treatments for irregular heartbeats, known as cardiac ablations.

    The Heart & Vascular Center of the Main Line has scheduled its first cardiac ablations this week. Horsham’s AMS aims to start offering those procedures in June. Victor’s King of Prussia group expects to add ablations in the future as well.

    Impact on hospitals

    It is too soon to know how the new surgery centers will impact the region’s existing health systems. In some cases, independent cardiologists generate significant patient numbers for hospitals’ cath labs.

    After Bryn Mawr Medical Specialists opened its cardiovascular surgery center near Main Line Health’s Bryn Mawr Hospital, the private group performed fewer procedures on low-risk patients at the hospital.

    To sustain patient volumes, Main Line has increased collaboration with other physician practices, while continuing to treat an “older patient population, whose more complex health conditions require the advanced expertise and emergency support only a hospital setting can provide,” officials said in a statement.

    In Horsham, most of the patients coming to AMS would have gone to Jefferson Abington Hospital before the surgery center opened in partnership with Atria Health, a private-equity backed group, Borge said.

    Jefferson declined to comment.

    King of Prussia’s Ambulatory Cardiovascular Center of Pennsylvania is opening through an unusual four-way partnership involving Cardiology Consultants of Philadelphia, Cardiovascular Logistics, SCA (a unit of UnitedHealth’s Optum), and the University of Pennsylvania Health System.

    “Ours is not going to seriously impact any one hospital system, which they’re all relieved about,” said Victor, who is also president of the Mid-Atlantic region for Cardiovascular Logistics. He said other health systems were invited to invest in the surgery center, but only Penn did so.

    Penn declined to comment for this article. On the Alvarez & Marsal What’s Your Moonshot podcast, the health system’s chief operating officer, Michele Volpe, recently said the system needs ”to move a bit faster in taking much of the work that we are doing in inpatient ORs and moving them into outpatient or ambulatory freestanding ORs.”

    AMS Cardiology’s ambulatory surgery center in Horsham is one of four new cardiovascular surgery centers in Southeastern Pennsylvania.

    Center City’s ReVaMP Health & Vascular Surgery Center wants to bring in cardiologists from nonaffiliated practices, and even the city’s big health systems. The facility opened last year, spearheaded by Re-Vasc Med Professionals’ two interventional cardiologists in partnership with Surgery Partners, a publicly traded manager of surgery centers nationwide.

    “I’m 100% sure this is going to be the trend of the future,” Re-Vasc CEO and founder Jon George said.

    A health insurer’s perspective

    Richard Snyder, a top executive at Independence Blue Cross, the largest health insurer in Southeastern Pennsylvania, has for years watched joint replacements and other procedures shift from hospitals to lower-cost surgery centers.

    The financial impact goes beyond the lower prices at surgery centers, he said, expecting that hospitals will not simply cede these patients to new competitors.

    Some hospitals might decide to take a lower payment for outpatient procedures. “Traditionally, that happens when we have capacity in lower-cost settings,” he said.

    At the same time, Medicare is pushing to pay the same price for services, wherever they are performed. “Hospitals, by necessity, will need to move some things to lower-cost settings in order to not lose money on them,” Snyder said.

  • Main Line Health reported an operating profit of $8.7 million in the first half of fiscal 2026

    Main Line Health reported an operating profit of $8.7 million in the first half of fiscal 2026

    Main Line Health had an $8.7 million operating profit in the six months that ended Dec. 31, the nonprofit health system reported to bond investors Wednesday.

    Main Line’s swing from an $8.9 million loss in the same period of 2024 benefited from a change in accounting for depreciation that reduced expenses. Without that change, Main Line would have had another loss.

    “We have been pleased with our continued improvement in fiscal performance year over year, which has been strong outside of the change in depreciation,” Main Line’s chief financial officer, Leigh Ehrlich, said in a statement.

    Here are more details on Main Line’s results:

    Revenue: Main Line reported $1.35 billion in patient revenue in the first six months of fiscal 2026, up 10.5% from $1.22 billion a year ago. Strong gains in hospital discharges, emergency department visits, and same-day surgeries contributed to the increase. Main Line’s Riddle Hospital near Media has seen a 36% increase in patients following the closure of Crozer Health’s hospitals last spring, contributing to revenue growth, Ehrlich said.

    Expenses: Last year, Main Line changed how it accounts for investments in facilities and equipment, significantly reducing depreciation and amortization expenses. In the first two quarters of fiscal 2026, Main Line’s depreciation and amortization expense was $68.8 million, down from $84.5 million the year before. Excluding those expenses from both years, Main Line’s operating profit margin fell slightly, to 5.5% from 5.9%.

    Notable: Main Line provides more detail than most systems on its patients’ health insurers. After just two years in Southeastern Pennsylvania, Pittsburgh insurance giant Highmark accounted for 12.5% for the business at Main Line Health. That is just 2 percentage points less than Aetna, which as been in the market for decades.

  • Temple Health reported a $50.5 million operating loss in the first half of fiscal 2026

    Temple Health reported a $50.5 million operating loss in the first half of fiscal 2026

    Temple University Health System had a $50.5 million operating loss in the six months that ended Dec. 31, the Philadelphia nonprofit told bond investors Monday. In the same period the year before, Temple reported a $13.5 million operating gain.

    Here are some details on Temple results:

    Revenue: Total revenue reached $1.64 billion, up 7.3% from the year before. Patient revenue rose 8% due mostly to increased outpatient revenue from Temple’s pharmacy business, infusions, and same-day surgeries. Two hits to revenue were a $14.3 million decrease in state funding and decline in the number of transplants, which bring in large amounts of revenue. Temple said it expects both of them to rebound in the remainer of fiscal 2026.

    Expenses: Temple attributed some of its loss in the first six months of fiscal 2026 to $20 million in extra expenses associated with the opening of its new Woman & Families Hospital, a $7.2 million increase in medical liability expenses, and a $6.4 million increase in losses under its Medicaid contract with Health Partners Plans.

    Notable: Despite its operating loss, even on a cash basis, Temple financial reserves increased to more than $1 billion as of Dec. 31. Most of the gain came from investments. The reserves equal the amount of money needed to keep the health system operating for 119 days if no more revenue came in. At the end of 2024, that figure was 113 days.

  • Penn Medicine had a $189 million operating profit in the first half of fiscal 2026

    Penn Medicine had a $189 million operating profit in the first half of fiscal 2026

    The University of Pennsylvania Health System had an operating profit of $189 million in the first six months of fiscal 2026, up from $117 million in the same period a year ago, the nonprofit reported to bond investors Friday.

    Operating income increased, even after Penn put $43 million put into reserves for medical malpractice claims. Two years ago, Penn had recorded charges totaling $90 million for the same purpose.

    Here are more details on Penn’s results:

    Revenue: Penn had $6.76 billion in total revenue, up nearly 12% even adjusting for the inclusion of Doylestown Health in fiscal 2026. Penn acquired Doylestown last April.

    “We’ve had good volume growth over the prior year, particularly in our outpatient activity,” the health system’s chief financial officer, Julia Puchtler, said in an interview.

    The system has also had an increase in the acuity level on the inpatient side, she said. That translated into more revenue.

    Expenses: The $43 million malpractice charge boosted overall malpractice expenses through December to $125 million, from $69 million in the same period a year ago.

    It’s not that Penn is seeing more claims, Puchtler said. “It’s really the average reserve per claim that we’re seeing accelerate,” she said.

    Notable: Excluding Doylestown, Penn saw a 5.9% increase in patient volumes, Puchtler said. “That’s mostly outpatient,” she said. “Outpatient surgery, endoscopy, and some of our other infusion therapy are all increased over the prior year.”

    Editor’s note: This article has been updated to reflect an additional medical malpractice charge in 2024, bring the total to $90 million.

  • Johnson & Johnson will spend $1 billion on a cell therapy plant in Montgomery County

    Johnson & Johnson will spend $1 billion on a cell therapy plant in Montgomery County

    Johnson & Johnson plans to spend more than $1 billion to build a cell therapy manufacturing facility in Montgomery County near Spring House, the New Jersey pharmaceutical and medical supplies giant said Wednesday.

    The Lower Gwynedd Township plant, part of an effort by the company to invest $55 million in the U.S. by early 2029, is expected to employ 500 people when fully operational in 2031, J&J said.

    The facility at 1201 Sumneytown Pike will add to J&J’s capacity to make cell therapy treatments for cancer, with a focus on multiple myeloma. That’s a type of cancer that attacks white blood cells in the bone marrow. Cell therapy is the use of engineered immune cells to treat disease.

    “Pennsylvania’s proud manufacturing legacy, from steel to today’s medicines and medical technologies and Johnson & Johnson’s roots here for seven decades, are part of why we are investing here.” Joaquin Duato, J&J’s chairman and CEO, said.

    Duato spoke during an event at the company’s Spring House research and development campus, where 2,500 scientists work in 70 laboratories. The Montgomery County site is J&J’s largest R&D center and it’s “where most of our discovery efforts start,” Duato said.

    The company based in New Brunswick, N.J., employs 5,885 people at 10 Pennsylvania facilities, according to the office of Gov. Josh Shapiro. The Shapiro administration has offered $41.5 million in state support for the J&J project.

    “With this investment, we are further cementing our place as a leader in life sciences,” Shapiro said. He said his administration’s efforts to cut red tape are among the reasons companies like J&J “are choosing to double down on their investments” in Pennsylvania.

    Eli Lilly & Co. last month announced plans to build a $3.5 billion pharmaceutical plant in the Lehigh Valley to expand manufacturing capacity for next-generation injectable weight-loss medicines.

    GSK said in September that it will build a biologics factory in Upper Merion Township, but did not specify how much it would spend there. That project is part of GSK’s plan to spend $1.2 billion on advanced manufacturing facilities.

    Johnson & Johnson chairman and CEO Joaquin Duato (left), was joined by Gov. Josh Shapiro and Pa. Dept. of Community and Economic Development Secretary Rick Siger (right) on Wednesday when J&J announced it will spend $1 billion on a cell therapy plant on its campus in Lower Gwynedd Township.

    Merck, another New Jersey-based drug giant, last year announced plans for a $1 billion factory and lab near Wilmington. Merck also has major operations in Montgomery County, which is among the top-ranked counties nationally for pharmaceutical manufacturing jobs.

    J&J has a long legacy in the Philadelphia region. Among its major acquisitions here was the 1959 purchase of McNeil Laboratories, which later developed Tylenol. The pain reliever is still made at a plant in Fort Washington.

    Other major Philadelphia-area J&J deals include the 1999 purchase of Centocor, one of the country’s first biotech companies, and the 2012 deal for Synthes Inc., a Swiss medical device maker with its North American headquarters and major operations here.

    Separately from the new cell therapy manufacturing facility, J&J has two expansion projects planned for the Spring House R&D site.

    One is a new cell engineering and analytical sciences facility. The other is focused on CAR-T testing and manufacturing during research and development, with the goal of creating personalized therapies more quickly and efficiently. The company did not disclose the cost of those projects.

  • Jefferson Health reported a $201 million operating loss in the first half of fiscal 2026

    Jefferson Health reported a $201 million operating loss in the first half of fiscal 2026

    Jefferson Health had an operating loss of $201 million in the six months that ended Dec. 31, compared to a $55 million loss the year before, the nonprofit health system said in a notice to bondholders Friday.

    The $201 million loss included a $64.7 million restructuring charge related to severance for 600 to 700 people laid off in October and other changes designed to improve efficiency in the 32-hospital system that stretches from South Jersey to Scranton.

    Excluding the restructuring expenses, Jefferson’s operating loss was $136.3 million in the first half of fiscal 2026.

    Jefferson said in a statement that it continues facing significant financial headwinds, like health systems nationwide, citing rising pharmaceutical costs.

    “We remain focused on driving efficiency, advocating for reimbursement rates that better reflect the true cost of care in Pennsylvania, and advancing the long-term stability of our academic health system,” the health system’s chief financial officer Michael Harrington said.

    Here are some details:

    Revenue: Patient revenue reached nearly $6 billion in the first half of fiscal 2026. The figure for the previous year is not comparable because it does not include Lehigh Valley Health Network for the full six months. Jefferson acquired the system on Aug. 1, 2024.

    Jefferson’s total revenue of $8.6 billion included $145.9 million of investment income that directly boosted operating income. Competitors who use heath-system reporting rules do not include investment income in revenue. Jefferson, by contrast, follows rules for higher-education reporting.

    Insurance business: Jefferson noted improvement in its health insurance arm. Jefferson Health Plans’ loss in the six months ended Dec. 31 was $90.7 million, compared to a $118.5 million loss in the same period the year before. The number of people insured in the plans climbed to 371,005 from 359,662. Medicaid recipients account for most of that enrollment.

    Notable: Both Moody’s Ratings and Standard & Poor’s Ratings Service in December and January revised their outlooks on Jefferson to negative, which means the agencies could downgrade the organization’s credit rating if Jefferson’s finances don’t improve over the next two years.

    “The negative outlook reflects the magnitude of current operating losses as well as anticipated difficulties in returning to or near operating profitability for several years,” Standard & Poor’s said.

  • Tower Health reported a $16 million operating loss in the first six months of fiscal 2026

    Tower Health had an operating loss of $16 million in the first six month of fiscal 2026, according to its report to bondholders Friday. In the same period a year ago, the Berks County nonprofit’s loss was $16.1 million.

    Here are some details:

    Revenue: Revenue from patient care rose less than 1% to $889.3 million, while total revenue climbed 4.3% to $1.03 billion, thanks to a 34% increase in other revenue.

    Cash reserves: Tower reported $244 million in cash reserves on Dec. 31. That translates into enough money to keep operating for 44 days without any new revenue. Both of those figures were at their highest levels since 2022.

    The quarterly low was in March 2024, when Tower reported $153 million in cash. That amounted to 30 days of cash on hand. Financially strong systems often have 200 days in reserve.

    Notable: In November, Tower announced that it was laying of 350 people, or about 3% of its workforce. Pottstown Hospital took the brunt of the cuts, though Tower also closed the bariatric surgery program at Reading Hospital in West Reading.

  • Family Practice & Counseling Services Network won a $3.4 million federal heath center grant

    Family Practice & Counseling Services Network won a $3.4 million federal heath center grant

    Family Practice & Counseling Services Network won a $3.4 million federal health center grant that will allow the nonprofit to continue providing medical and mental healthcare in Southwest Philadelphia and other low-income Philadelphia neighborhoods, officials confirmed this week.

    The clinic had been part of Resources for Human Development, a Philadelphia human services agency that a fast-growing Reading nonprofit called Inperium Inc. acquired in late 2024. As a federally qualified health clinic since 1992, the clinic had received an annual federal grant, higher Medicaid rates, and other benefits.

    Federal rules prohibited the clinic from continuing to retain that status and those benefits under a parent company. That meant Family Practice & Counseling Network had two options: close or spin out into a new entity that would reapply to be a federally qualified clinic.

    With financial and operational help from the University of Pennsylvania Health System, Family Practice & Counseling formed a new legal entity last July and reapplied for the grant. Last week, the organization’s CEO Emily Nichols learned that the federal agency that oversees federal health centers awarded it the grant.

  • ArchWell Health is a new primary care provider for Philadelphians with Medicare Advantage

    ArchWell Health is a new primary care provider for Philadelphians with Medicare Advantage

    A new sign with orange letters outside a former Rite Aid in Germantown announces the arrival of a primary care model new to the Philadelphia region.

    ArchWell Health recently opened its first three of eight planned primary care centers here for people with Medicare Advantage, promising convenient and personalized care in neighborhoods with a relative lack of doctors.

    Two others have opened on North Broad Street, near Stenton and Susquehanna Avenues, also in former Rite Aid stores.

    A privately held company based in Nashville, Tenn., ArchWell says it can offer patients greater access to healthcare through lower patient-provider ratios.

    It plans to limit each of its physicians to no more than 500 patients — about a fifth of the patient load for typical primary care doctors. Nurse practitioners working under the doctors will manage a maximum of 250 patients, officials said.

    The approach is built around a financial model that differentiates ArchWell from Medicare-focused competitors already in Philadelphia like Oak Street Health and ChenMed’s Dedicated Senior Medical Centers. ArchWell only accepts patients who have private Medicare or are willing to switch to it. Oak Street and ChenMed also accept traditional Medicare.

    Privately run Medicare Advantage plans are increasingly popular among people ages 65 and older who qualify for government-funded Medicare coverage. Advantage plans appeal to people by covering services, such as dental and vision care, left out of traditional Medicare, but have come under scrutiny for exaggerating how sick patients are to rack up more revenue.

    ArchWell sees exclusively working with Medicare Advantage plans as helping doctors to focus solely on the best outcomes for patients, rather than on providing more services to bring in more revenue, a criticism of traditional Medicare, said Doron Schneider, its medical director for the Philadelphia market.

    Melissa A. Herd, community relations specialist for ArchWell Health in Philadelphia, is shown outside the company’s Germantown location, which is in a former Rite Aid building.

    “You have different incentives, you have different care models, you have different case management models, you have different ways to treat one person versus the other,” Schneider said.

    Before starting at ArchWell in late 2024, Schneider worked at Tandigm Health, an Independence Health Group company founded in 2014 with the goal of helping primary care doctors manage costs and improve care for their patients. He learned there how hard it is for doctors to work with different types of insurers and the varied incentives that go with them.

    How ArchWell conducts business

    ArchWell, which opened its first clinic in 2021 in Birmingham, Ala., operates under contracts with Medicare Advantage plans. The plans give ArchWell a portion of the monthly payment they get from Medicare for each patient. That money is supposed to cover all of the person’s medical costs.

    Aetna, UnitedHealthcare, and Devoted Health have contracts with ArchWell to cover the Philadelphia market. ArchWell is close to getting contracts with HealthSpring and Humana, Schneider said. Those five companies had more than 90,000 people in their plans in December, according to federal data.

    Aetna and UnitedHealthcare said they work with clinics like ArchWell’s around the country to improve health outcomes and leave patients more satisfied with their experience.

    “We are pleased that they are now an option for Aetna Medicare Advantage members in the Philadelphia area,” Aetna said in a statement.

    ArchWell declined to provide financial details, such as annual revenue from the more than 80 clinics it had in a dozen states before coming to Philadelphia or how much it spends to open each center. ArchWell representatives also did not disclose who its owners are.

    The interior of Archwell Health’s Germantown primary care clinic has Philadelphia-centric images painted on the walls.

    Company founder Carl Whitmer worked at Clayton, Dubilier & Rice, a global private equity firm, before founding ArchWell.

    “We have partners that are focused on our sustainability and growth,” said Christina Cober, ArchWell’s vice president of marketing.

    But companies focused on primary care for seniors haven’t always been as successful as anticipated.

    Oak Street, founded in Chicago in 2012, grew rapidly and now services 450,000 patients at 230 centers across the country. It declined to say how many patients it has in Philadelphia. Oak Street arrived here in 2018.

    CVS Health bought Oak Street in 2023 for $10.6 billion, anticipating that it would expand to more than 300 centers by this year. Last fall, CVS announced it was closing 16 centers and taking a $5.7 billion write-down on its health-services business, largely because of slower anticipated growth at Oak Street.

    Patina Health, a Bala Cynwyd company that offered virtual and in-home primary care for Medicare Advantage patients through a partnership with Independence Blue Cross, shut down last year due to “unforeseen business challenges.”

    How ArchWell approaches patient care

    ArchWell says its lower patient-provider ratios allow more frequent interactions with patients. If a patient is diagnosed with high blood pressure, Schneider said, the message to the patient is: “We’ll see you back in a week. We’ll see you back in two weeks.”

    The repeat visits happen with no cost to the member and no extra revenue to ArchWell because all care is supposed to be covered by a monthly payment per member.

    ArchWell expects to add about 300 patients per year at each center, said Cober. Staffing at the centers starts out with a physician, a nurse-practitioner, two care navigators, two medical assistants, and a center manager.

    Among the early patients at ArchWell’s center on Germantown Avenue is Marcella James, 69, who lives across the street from the clinic and watched as the building was transformed from a shuttered Rite Aid.

    “I walked over there one day just to see what it was like and what they offer, and I signed up right away,” James said. James likes her doctor at Temple Health, but ArchWell was irresistibly convenient.

    “If I can get the same help or better help from ArchWell is to be seen because I just started with them,” she said.